Pharmaceutical Research & Development (Track)


Adrián Angel Inchauspe

Research Department, "Dr. Alejandro Korn" Hospital, Argentina


According to Frontiers Editorial, "Torsadogenic Index." it became one of the most consulted articles of this journal, being referred in several papers published in several websites Torsadogenic Index allows evaluation of QT prolongation respect to those drugs listed as causing Torsade de pointes. To be predictive of potential deaths due to pharmaceutical fatal drug indications, Torsadogenic Index may markedly reduce the impact of death risk by prescription and / or drug interaction, unfortunate consequence of the lack of a responsible strict clinical control and cardio -surveillance of collateral effects. Being an event of uncertain evolution, this Risk Management Project attempts to reduce its Occurrence Probability Impact. It is well known current concern of Pharmacological Global Regulatory Committees, regarding the withdrawal of drugs that show their "sentinel effect" after its commercialization on market. Today, in U.S. alone, 1.5 million individuals are affected requiring hospitalization because of side reactions or drug interactions, of which 100,000 die each year for the same reason. Established itself as the fourth leading cause of death in the United States, actual need of mandatory registration based upon Torsadogenic Index will inaugurate a systematic risk assessment referred to as a contingency measure, reducing the impact factor of this hardly reversible condition. The goal of the Planned Risk Management is to optimize the success of this project, preventing fatal risk to become into a leading problem.  Making this happen is synonymous of having successfully managed the risk.